Special envoy of Denmark comes to discuss the future of European Medicines Agency

Medicine
DELFI / Karolina Pansevič

On 8 February 2017 the Danish government has announced that Denmark will work towards getting the EMA relocated from London to Copenhagen, when the United Kingdom leaves the EU.
With the strong Danish tradition for safeguarding patient safety, an important research environment and a thriving and innovative pharmaceutical industry, Denmark has excellent preconditions for hosting the European Medicines Agency when the agency, including its 900 employees, will be relocated as a consequence of Brexit. That is the message from the Danish government which now bids to host the EMA in Copenhagen.

The EMA is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. The Agency therefore plays a key role in ensuring that medicinal products are safe, effective, and of a high quality. For that reason, the Ministry of Health will also play an important role in attracting the EMA to Copenhagen in the coming months.
As part of the candidacy, the government has appointed Lars Rebien Sørensen, former CEO of Novo Nordisk, as special envoy of the government. With his in-depth knowledge of the pharmaceutical sector and large international network, Lars Rebien Sørensen will work closely with the government in the coming months on the Danish candidacy.

You may like

Be the first to comment

Leave a Reply

Your email address will not be published.


*